Arcus Q4 net loss $81M; cash to $1.2B after Gilead; streamlines TIGIT program; casdatifan shows promise

Arcus Biosciences, Inc.

2023-FY EPS reported -$4.15 revenue$117,000,000

Net loss of $81M in Q4 2023 ($307M full year); revenue $31M Q4 2023 vs $34M Q4 2022.
Pro forma cash $1.2B after $320M equity investment from Gilead in Jan 2024; funding into 2027.
Discontinued ARC-10 Phase 3 in PD-L1-high NSCLC; accelerating STAR-121; planning STAR-131 in perioperative NSCLC.
Casdatifan (HIF-2a) Phase 1 data: 20 mg dose achieved similar EPO suppression as 120 mg belzutifan; no DLTs.
Quemliclustat in pancreatic cancer: median OS 15.7 months in pooled ARC-8 analysis; Phase 3 planned early 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcus Biosciences, Inc. reported financial results for the three months and full year ended December 31, 2023.

Period: the three months and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 21, 2024, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001724521-24-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.